Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Carvykti
Pharma
Legend CEO talks BIOSECURE Act, M&A rumor and Carvykti growth
Legend is taking "a close look at" its business, speaking with lawmakers and investors about recent geopolitical and M&A speculations, its CEO said.
Angus Liu
Aug 9, 2024 10:30am
J&J partner Legend Biotech reportedly receives buyout offer
Jul 15, 2024 11:06am
Eisai, Takeda, BIOSECURE—Fierce Pharma Asia
Jul 12, 2024 9:05am
J&J, Legend's Carvykti extends lives in multiple myeloma trial
Jul 2, 2024 9:58am
J&J reports $133M in sales for new multiple myeloma med Tecvayli
Apr 16, 2024 11:28am
Geopolitical tensions, Carvykti, Enhertu—Fierce Pharma Asia
Apr 12, 2024 8:20am
